SCM
REVB icon

Shaolin Capital Management’s Revelation Biosciences REVB Stock Holding History

Shaolin Capital Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed -$2.48M – 945
2021
Q4 		$2.48M Hold
1
– – 0.06% 362
2021
Q3 		$2.45M Hold
1
– – 0.07% 283
2021
Q2 		$1.64M Hold
1
– – 0.05% 305
2021
Q1 		$1.47M Buy
+1
New +$2.05M 0.06% 280

Other funds holding REVB

Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Shaolin Capital Management's REVB Position: Q1 2022 in Review

Shaolin Capital Management sold out of Revelation Biosciences (REVB) in Q1 2022, closing a stake of 1 share — an estimated $2.48M sold.

Shaolin Capital Management first reported a position in REVB in Q1 2021 and held it in 4 quarters. The position peaked at $2.48M in Q4 2021. 2 funds tracked by Wall St. Rank hold REVB as of Q1 2022.

  • Shaolin Capital Management reported no remaining Revelation Biosciences position as of Q1 2022 after selling out during the quarter.
  • Shaolin Capital Management sold 1 Revelation Biosciences share in Q1 2022, an estimated $2.48M.
  • Shaolin Capital Management first reported a position in Revelation Biosciences in Q1 2021 and held it in 4 quarters.
  • Shaolin Capital Management's Revelation Biosciences position peaked at $2.48M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2022.

Based on Shaolin Capital Management's 13F filing for Q1 2022, filed 13 May 2022.